Tessera
Folgen

Talha Badar

@talhabadarmd.bsky.social

Hematologist-Oncologist at Mayo Clinic. Interest in Acute Leukemia and Myeloid disorders.

9 Posts15 Follower8 Folgt
Talha Badar@talhabadarmd.bsky.social · 4d ago

Exciting #DELPHINUS results: Dara + chemo achieved 83% ORR, with 75% proceeding to allo-HSCT and 24-month OS of 41% in R/R T-ALL. As EA9213 co-chair, excited to see whether Dara can eradicate MRD and deepen remission in T-ALL. #TcellALL #Leusm doi.org/10.1182/bloo...

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce

doi.org

Talha Badar@talhabadarmd.bsky.social · 4d ago

@bloodjournal.bsky.social study evaluated using leukemia cell lines Ziftomenib ⬇️ MEIS1/HOXA signaling, induced differentiation, and caused leukemia regression in NPM1/KMT2Ar CRISPR-engineered MEN1-mt models showed activity > T349M & G331R—but resistance> M327I/G331D. #AML doi.org/10.1182/bloo...

Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models

Key PointsZiftomenib shows pronounced preclinical activity in the menin-KMT2A–dependent leukemia models, including patient-derived xenografts.Ziftomenib de

doi.org

Talha Badar@talhabadarmd.bsky.social · 4w ago

@VuMedi talk on our COMMAND Consortium study in Ph+ ALL. Early CMR (3 months) identifies patients with excellent outcomes. AlloHCT reduced relapse but did not improve OS, supporting a more individualized, MRD-guided transplant strategy. #Leukemia #PhALL #HemOnc www.vumedi.com/video/predic...

Predictors of Complete Molecular Response and AlloHSCT Outcomes in Philadelphia Chromosome–Positive ALL: The COMMAND Study

A video from Talha Badar, posted on Jul 14, 2026.

vumedi.com

OncoDaily@oncodaily.bsky.social · 4mo ago

Submissions Open for Special Issue on Evolving Paradigms in Acute Myeloid Leukemia - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Talha Badar: Submissions Open for Special Issue on Evolving Paradigms in Acute Myeloid Leukemia - OncoDaily

Talha Badar: Submissions Open for Special Issue on Evolving Paradigms in Acute Myeloid Leukemia / AML, cancer, OncoDaily, Oncology, Talha Badar

oncodaily.com

Talha Badar@talhabadarmd.bsky.social · 10mo ago

x.com/talhabadarmd...

Talha Badar on X: "#Weekend_review #ALL #leusm #CART Optimal utilisation of CAR T-cell in B-cell ALL 🧵 1/ Currently approve CAR T-cell for B-cell ALL 👇🏽 R/R to at least 2 prior line. Increasingly considered for persistent MRD+ not eligible for BMT. https://t.co/FkvT9dLPkF" / X

#Weekend_review #ALL #leusm #CART Optimal utilisation of CAR T-cell in B-cell ALL 🧵 1/ Currently approve CAR T-cell for B-cell ALL 👇🏽 R/R to at least 2 prior line. Increasingly considered for persistent MRD+ not eligible for BMT. https://t.co/FkvT9dLPkF

x.com